Black Rock Inc. Cyclo Therapeutics, Inc. Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
A detailed history of Black Rock Inc. transactions in Cyclo Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 59,510 shares of CYTH stock, worth $33,920. This represents 0.0% of its overall portfolio holdings.
Number of Shares
59,510
Previous 37,126
60.29%
Holding current value
$33,920
Previous $51,000
47.06%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding CYTH
# of Institutions
20Shares Held
2.25MCall Options Held
0Put Options Held
0-
Epiq Capital Group, LLC San Francisco, CA739KShares$421,4720.18% of portfolio
-
Vanguard Group Inc Valley Forge, PA599KShares$341,2550.0% of portfolio
-
Founders Fund V Management, LLC San Francisco, CA481KShares$274,0037.36% of portfolio
-
Geode Capital Management, LLC Boston, MA152KShares$86,8290.0% of portfolio
-
Founders Fund Vi Management, LLC San Francisco, CA110KShares$62,71318.16% of portfolio
About Cyclo Therapeutics, Inc.
- Ticker CYTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 8,439,440
- Market Cap $4.81M
- Description
- Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of...